Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Ginkgo Biloba wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
9 of 13 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
120-240mg standardized extract
With meals, Split into 2-3 doses
Standardized extract capsules (EGb 761)
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
12-24 weeks
8-12 weeks
First week
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Can We Use Ginkgo biloba Extract to Treat Alzheimer's Disease? Lessons from Preclinical and Clinical Studies
Cells (2022) · Meta analysis · n=2100
GBE was shown to reduce the escape latencies in several studies, in both rats and mice (I2 > 70%, p < 0.005).
Beneficial effects of Ginkgo biloba leaf extract on inflammatory markers: A systematic review and meta-analysis of the clinical trials
Phytotherapy research : PTR (2022) · Meta analysis · n=1104
In the meta-analysis, the weighted mean differences (WMD) in change for serum CRP were -1.5 mg/L (95% CI: -2.16, -0.85, p < 0.001).
Miscellaneous treatments for antipsychotic-induced tardive dyskinesia
The Cochrane database of systematic reviews (2018) · Meta analysis · n=1278
Studies were primarily of short (three to six6 weeks) duration with small samples size (10 to 157 participants), and most (61%) were published more than 20 years ago.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Based on multiple meta-analyses including 2100+ participants showing benefits in mild dementia and memory. Effects modest and primarily in older adults or those with existing cognitive decline. Standardized extract (EGb 761) preferred.
AI-estimated from published studies. Interpret as directional guidance.
Ginkgo Biloba has a higher evidence score (7/10 vs 8.5/10) and wins in 2 of 3 categories.
No known interactions between Ginkgo Biloba and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.